Sleep Disorders

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

Krithika Subramanian, PhD discusses the orexin receptor pathway, signals within orexin receptors, and much more surrounding the clinical application of orexin receptor antagonists.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered her perspective on the adherence challenges in treating obstructive sleep apnea with continuous positive airway pressure.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine provided her perspective on the differences in OSA prevalence for men and women.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered perspective on the currently available interventions for OSA, including the use of upper airway neurostimulation.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed the importance of identifying and diagnosing obstructive sleep apnea as a prevention for a number of its consequential risk factors.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed the importance of identifying and diagnosing obstructive sleep apnea as a prevention for a number of its consequential risk factors.

The senior director of Global Clinical Science at Takeda Pharmaceutical offered perspective on the development of TAK-925, an investigational selective orexin type-2 receptor agonist for the treatment of narcolepsy.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine spoke about the challenge of OSA being underdiagnosed, and what her institution is doing to combat it.

Neurology News Network for the week ending October 5, 2019.

The chief medical officer at Harmony Biosciences discussed the takeaways from a number of data presentations of pitolisant’s efficacy and safety from World Sleep 2019.

Year-long data presented at World Sleep 2019 suggest that Eisai’s lemborexant is safe and effective in treating adults with insomnia, supporting its recently submitted NDA. It is set to be reviewed by the FDA by late December.

Data presented at World Sleep 2019 has suggested that the investigation Jazz Pharmaceuticals sodium oxybate agent, JZP-258, is efficacious and safe in treating patients with narcolepsy who have cataplexy.

The analyses focus on the abuse potential, efficacy in high-burden patients with narcolepsy, and safety data for Harmony Biosciences’ histamine H3 receptor-antagonist/inverse agonist, pitolisant.

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City.

As new dual orexin receptor antagonists become available to treat sleep disorders, time will tell whether this new class of drugs will fulfill its promise for a disorder plagued by underdiagnosis and indifference.

Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.